What lessons do recent Ebola outbreaks in Africa offer for India's pandemic preparedness and vaccine R&D ecosystem?

On 17 May 2026, WHO declared the Bundibugyo Ebola outbreak in the DRC and Uganda a Public Health Emergency of International Concern under the International Health Regulations (2005). No licensed vaccine or specific treatment exists for this strain [1]. Africa's recent outbreaks show that results depend on preparation done before an outbreak starts. That lesson applies directly to India.

Lessons for pandemic preparedness

• Basic public health ends outbreaks first: In 2022, candidate Sudan-virus vaccines reached Uganda in a record 79 days. Contact tracing and isolation had already ended the outbreak (164 cases, 77 deaths) before the trial could begin [2]. India needs strong IDSP surveillance, district rapid-response teams and isolation beds.
• Pre-positioning saves time: When Sudan virus returned in 2025, candidate vaccine doses were already prepositioned in Kampala. Trial access began within days [3]. India should keep pre-approved trial protocols, ethics clearances and stockpiles ready for priority pathogens.
• Risk crosses borders: The PHEIC covered two countries [1]. India needs better port-of-entry screening and a One Health approach to zoonotic spillover.

Lessons for the vaccine R&D ecosystem

• Markets fail for pathogens that cause only occasional outbreaks: WHO's Ebola/Marburg R&D Roadmap says commercial markets for these vaccines are weak [4]. So the U.S. government gave IAVI $36 million, under a contract worth up to $99 million, for a single-dose Bundibugyo candidate [5]. India likewise needs public "push" funding through ICMR and DBT, paying for research before any market exists.
• Vaccines are species-specific: Ervebo is licensed only against the Zaire species. Its use against Bundibugyo is being tested with 20,000 doses in a Phase 3 trial [6]. India should invest in platform technologies (viral-vector, mRNA) that can be adapted quickly to a new strain.
• Manufacturing is India's strength, discovery is its gap: The Oxford–Serum Institute of India Bundibugyo candidate entered a Phase 1 trial in July 2026 [7]. India should link this manufacturing scale to home-grown discovery, BSL-4 capacity (ICMR-NIV Pune) and clinical-trial networks.

The Ebola outbreaks show that vaccines take years to develop while outbreaks spread in weeks. India therefore needs fast surveillance and containment now, plus a research pipeline that is ready before the next outbreak. Following the approach of WHO's R&D Blueprint [8] would strengthen India's health security, advance SDG 3.d and support India's role as a vaccine supplier to the Global South.